Management of hepatitis C virus coinfection in HIV-infected persons

AIDS Reader

Volumn 16, Issue 6, 2006, Pages

  O'Leary, Jacqueline G ^a,b   Chung, Raymond T ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HCV treatment; Hepatitis C; HIV HCV coinfection; HIV AIDS; Liver disease

Indexed keywords

ALPHA2A INTERFERON; ANTIRETROVIRUS AGENT; DIDANOSINE; ERYTHROPOIETIN; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MONOTHERAPY; NEUTROPENIA; PANCREATITIS; PREVALENCE; PROGNOSIS; REVIEW; THROMBOCYTOPENIA;

EID: 34447283526     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121-130.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341: 556-562.
3. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology. 1998;45(suppl 3):1206-1213.
4. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
5. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-1440.
6. Degos F. Vaccination against hepatitis B virus: ANAES and INSERM experts take a view [in French]. Gastroenterol Clin Biol. 2004;28:50-53.
7. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998;28:562-567.
8. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996;31:552-558.
9. Rosenberg PM, Farrell JJ, Abraczinskas DR, et al. Rapidly progressive fibrosing cholestatic hepatitis - hepatitis C virus in HIV coinfection. Am J Gastroenterol. 2002;97:478-483.
10. + T-cell count in individuals coinfected with HIV-1. Blood. 2005;105: 1170-1178.
11. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84:1020-1023.
12. Verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HW-hepatitis C virus-coinfected patients? Clin Infect Dis. 2006;42:262-270.
13. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993;6:602-610.
14. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
15. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS. 2004;18:2163-2170.
16. Iyer RV, Atten MJ, Attar BM, et al. HIV/HCV coinfected patients display increased perisinusoidal hepatic stellate cell activation and less inflammation activity. Hepatology. 2005;42:913A.
17. Danta M, Semmo N, Northfield J, et al. HCV-specifc T-cell responses of acutely HCV infected individuals with and without HIV. Hepatology. 2005; 42:920A.
18. Grebely J, Conway B, Raffa J, et al. Natural history of hepatitis C virus infection among injection users in Vancouver, Canada. Hepatology. 2005;42: 87A.
19. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713-720.
20. Blackard JT, Smeaton L, Hiasa Y, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis. 2005; 192:258-265.
21. Macias J, Japon MA, Saez C, et al. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis. 2005;192: 1566-1576.
22. Munshi N, Balasubramanian A, Koziel M, et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis. 2003;188:1192-1204.
23. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002;16:1915-1923.
24. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS. 1998;12:2289-2293.
25. Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005;43:78-84.
26. Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by liver stiffness measurements in HIV-HCV coinfected patients: a prospective study. Hepatology. 2005;42:630A.
27. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother. 2005;49:3997-4008.
28. Sherman KE. High frequency of anemia in HCV-HIV coinfected persons receiving weight-based ribavirin and zidovudine. Hepatology. 2005;42:1230A.
29. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
30. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
31. Gonzalez-Garcia J, Moreno S, von Wichmann M, et al. Association between sustained virological response (SVR) and ALT levels in HIV-HCV coinfected patients who received peginterferon alpha-2a (40kD) (Pegasys) plus ribavirin (Copegus) in the AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT). Hepatology. 2005;42:1167A.
32. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292:2839-2848.
33. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003;188:1412-1420.
34. Ragni MV, Eghtesad B, Schlesinger KW, et al. Pre-transplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005;11:1425-1430.
35. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet. 1996;348:283-291.
36. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-1090.
37. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349:1413-1421.
38. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585-592.
39. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
40. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet. 1997;349:924-925.
41. Bruno R, Sacchi P, Maiocchi L, et al. Hepatotoxicity and nelfinavir: a meta-analysis. Clin Gastroenterol Hepatol. 2005;3:482-488.
42. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001;98:12671-12676.
43. Fuster D, Clotet B. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother. 2005;6:1565-1572.
44. Nevirapine (Viramune) prescribing information. Ridgefield, Conn: Boehringer Ingelheim, January 2005. Available at: http://bidocs. boehringeringelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt& folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf. Accessed May 9, 2006.